Dr. Adrian G. Murphy

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Gastroesophageal Junction Cancer.

Jose Mendoza is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Mendoza is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Familial Colorectal Cancer. Dr. Mendoza is currently accepting new patients.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Gastroesophageal Junction Cancer.